Hyper-activation of PPARγ signaling, either due to PPARG gene amplification or an RXRα hotspot mutation (S427 F/Y), can be pharmacologically inhibited with PPARγ-selective inverse agonists that decrease the viability of PPARγ-dependent bladder cancer cells. This evidence concerns the gene RXRA and urinary bladder carcinoma.